Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2017			10,000	9,484,000
Beginning Balance at Dec. 31, 2017	$ 50,189	$ 50,507	$ 0	$ 9	$ 433,044	$ (28)	$ (381,810)	$ (708)	$ (318)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,984)	(4,982)					(4,982)		(2)
Unrealized loss on marketable securities	(31)	(31)				(31)
Share-based compensation (in shares)				79,000
Share-based compensation	103	103		$ 1	102
Proceeds from option exercises (in shares)				12,000
Proceeds from option exercises	40	40			40
Change in ownership in subsidiary	0	(48)			(48)				48
Ending Balance (shares) at Mar. 31, 2018			10,000	9,575,000
Ending Balance at Mar. 31, 2018	45,317	45,589	$ 0	$ 10	433,138	(59)	(386,792)	(708)	(272)
Beginning Balance (shares) at Dec. 31, 2018			10,000	9,866,000
Beginning Balance at Dec. 31, 2018	37,454	37,726	$ 0	$ 10	436,433	(32)	(397,977)	(708)	(272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of accounting standard	(62)	(62)					(62)
Net loss	(4,365)	(4,367)					(4,367)		2
Unrealized loss on marketable securities	14	14				14
Share-based compensation (in shares)				96,000
Share-based compensation	417	417			417
Net proceeds from issuance of common stock (in shares)				431,000
Net proceeds from issuance of common stock	1,000	1,000			1,000
Ending Balance (shares) at Mar. 31, 2019			10,000	10,393,000
Ending Balance at Mar. 31, 2019	$ 34,458	$ 34,728	$ 0	$ 10	$ 437,850	$ (18)	$ (402,406)	$ (708)	$ (270)